Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.

Fiche publication

Date publication

octobre 2026

Journal

European journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Rival M, Rollot F, Laurent-Chabalier S, Casey R, El Bahi I, Brocard G, Marignier R, Trouillet-Assant S, Vukusic S, Fromont A, Laplaud DA, Mathey G, Maillart E, Michel L, Ruet A, Labauge P, Ayrignac X, Zephir H, Ciron J, de Sèze J, Kwiatkowski A, Papeix C, Branger P, Lebrun-Frenay C, Berger E, Clavelou P, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Créange A, David T, Magy L, Camdessanche JP, Doghri I, Dos Santos A, Mura T, Agherbi H, Thouvenot E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42798289

Résumé

Serum neurofilament-light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO).